

Index

- A1 adenosine receptors, 234
- ABT-737 (small molecule inhibitor), 234–235
- ACC2 knockout mice, 231–232
- accessible biomarkers, 295, 303, 305, 306, 309
- acetaminophen (APAP)
 - Ab Initio* analysis of oxidation of, 108
 - chronic intermittent hypoxia (CIH), 57
 - covalent binding by, 116
 - hepatotoxicity, 63, 115
 - P450-mediated bioactivation of, 103
- acetylcholinesterase (AChE), 141
- action potential duration (APD), 38, 42, 49
- acute and chronic toxicity (fish models), 251–252
- adalimumab (Humira), 330
- adaptive immune system, 124–125, 360–361
- adenosine triphosphate (ATP) analogs/ binding sites, 212
- ADME (absorption, distribution, metabolism, and excretion) properties, 77, 167, 183, 246, 325, 372
- ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties, during lead optimization
- early profiling components, 189–194
 - in vitro safety profiling data generation confidence in data, 191–193
 - relevance of data, 193–194
 - in vitro toxicology, 189–190
- outline of need for, 184–189
 - clinical candidate selection, 188–189
 - hit expansion, 196–197
 - lead nomination, 187–188
 - lead optimization/parallel optimization, 188
 - target selection, 185–186
- adolescents
 - cancer in, 225
 - paroxetine pharmacokinetics measurements, 56
- adverse drug reactions
 - adaptive immune system mediation of, 124–125
 - mediated by innate immune system
 - nucleic acids stimulating Toll-like receptor 9, 127–129
 - nucleic acids stimulating Toll-like receptors 7 and 8, 129
- AIDS therapy, 154
- albuminuria (as biomarker), 304, 306
- alcoholic liver diseases (ALDs), 58
- alkylating agents, 176, 205–206
- alpidem, 54, 114
- Ames assay, 211
- amodiaquine, 106
- amphetamine, 144
- Angiotensin II biomarker, 306
- animal testing (models). *See also* dog models; genetically engineered mice (GEMs) models; guinea pig models; knockout mice; monkey models; pig (minipigs) models; rabbit models; rat models
 - autoimmunity and, 357
 - chick embryo neural retina cell culture model, 160, 165
 - genetically modified animals, 155–157
 - nuclear receptor studies, 97
 - pigs (minipigs), for intradermal/patch dosing assessments, 349
 - predictive value of, 7–11
 - rabbits, 349, 350
 - species selection criteria (for vaccine studies), 347–348
 - toxicogenomics studies, 284
 - whole embryo culture (rodents), 161–162
- anti-angiogenic agents, 206
- anti-hormonal agents, 205–206
- anti-metabolites, 205–206
- antibody drug conjugates (ADCs), 339
- antihistamine drugs, 187–188
 - See also* cetirizine; fexofenadine
- antioxidant response element (ARE), 60, 277
- antioxidants, 58, 63

- antipsychotic agents, 111
- Aplysia* (marine snail), 146
- AR-M100390 delta-opioid, 237
- Ara9(*fxneo/fxneoA*) hypomorphic mouse strain, 272
- L-Arginine biomarker, 306
- aripiprazole, 64
- ArrayExpress, 285
- ArrayTrack, 285
- arterially perfused wedge left ventricular preparations, 43–44
- aspirin, 58–59
- Assymetric-/Symmetric-Dimethylarginine biomarker, 306
- Ataxia Telangiectasia, 26
- atenolol, 111
- attrition, 2–4. *See also* derisking
 - developmental toxicity-mediated drug attrition
 - DMPKs, 230
 - economic consequence determinants, 153
 - NDAs, 230
 - optimal timing for, 3–4
 - reasons for, 3
 - from teratogenicity, 177, 230–231
- autoimmunity
 - animal models, 357
 - bioinformatics, 355–356
 - predicting, 354–355
 - risk and vaccination, 353–354
- autonomic nervous system, 37, 45, 48
- BACE1 knockout mice, 273
- Bacillus subtilis* hepatotoxicity, 59
- bacterial reverse-mutation tests, 18
- Bayesian networks, 293
- BCI-X₁ knockout mice, 231–232
- benoxapofen, 54
- benzimidazole class of proton-pump inhibitors, 114
- beta-lactams, 124
- bevacizumab (Avastin), 330
- bioassays
 - deficiencies in, 12
 - improvement recommendations, 12–14
 - tumor interpretation/risk assessment finding evaluations, 12
- Biochemical Pathways wall charts (Boehringer-Mannheim/Roche Applied Science), 293
- biodistribution studies for nucleic acid/DNA and viral vector-based vaccines, 352
- bioinformatics, 18, 354–356
- biological pathways and networks, 292–294
- bioluminescence testing, 21
- bioluminescent reverse mutation assay, 21
- Biomarker Qualification Review Teams (FDA), 308
- biomarkers for drug safety. *See also* Hy's Law
 - accessible biomarkers, 295, 303, 305, 306, 309
 - for cardiac injury/cardiac dysfunction, 305–306
 - chemical toxicity/disease overlap, 302–303
 - classifications, 304
 - current status of, 303–308
 - defined, 302
 - development of, 13
 - ex vivo*, 15
 - FDA review teams, 310–311
 - gene expression microarray technology and, 303
 - gene transcripts/miRNAs, 303
 - genomics biomarkers, 288–289
 - liver function, 307–308
 - needs for improvements, 308–310
 - predictive biomarkers, 304–305
 - regulatory acceptance qualifications, 310–311
 - for renal toxicities, 306–307
 - safety, xi
 - scope of, 302–303
 - vaccines, 360
 - vascular injury/associated inflammation, 306
- black-box warnings
 - CAST and, 183
 - DILI/drugs, 54
 - marketed drug databases and, 195
 - 1975–1999 from IADRs, 102
- bleomycin, 205–206
- blood brain barrier (BBB), 136, 141
- antihistamines (second generation) and, 147
 - permeability assessment, 149
- Blooms syndrome, 26
- Borrelia burgdorferi*, 355
- brain natriuretic peptide (BNP), 306
- Bristol Myers-Phylonix-Squibb test
 - collaboration, 170
- bromfenac, 54
- Brugada syndrome, 38
- Buehler occluded patch test, 126
- bupirone, 58–59, 67, 108, 116
- C-reactive protein (CRP) biomarker, 306
- cadmium, 144
- Caenorhabditis elegans* (nematode), 146, 147
- calcium channel blockers, 42
 - See also* verapamil
- Campylobacter jejuni* studies, 354–355
- cancer. *See also* oncology drugs/therapy
 - adolescents/children, 225
 - animal models, 128, 214, 215

- anticancer therapeutics, 9, 76
- antibody drug conjugates (ADCs), 339
- cytotoxicity, 8, 326
- hepatotoxic injury predictions, 9
- ICH S9 guidance document, 219
- late-stage patients, 205–206
- long-term chemotherapeutic studies, 224–225
- MTD determination, 314
- PATCH/SMO, 254
- toxicology/pathology challenges, 206–207
- vaccine development, 344
- breast cancer, 330, 338
- cancer-prone diseases, 26
- colorectal cancer, 330
- congestive heart failure (CHF) and, 195
- GEM carcinogenic studies, 276
- genotoxicity, 253
- global impact, 204–205
- human neuroendocrine (NE), 295–296
- logistic regression for prediction, 318
- protein overexpression, 234–235
- risk assessment paradigm, 18
- shh signaling pathway, 254
- candidate selection and attrition, 2–4
- carcinogenicity studies, 11, 12, 18, 276, 302, 346
- Carcinogenicity Working Group, 13
- Cardiac Arrhythmia Suppression Trial (CAST), 183
- cardiac injury/cardiac dysfunction markers, 305–306
- cardiac safety, 9. *See also* hERG channel; Torsade de pointes (TdP)
- assessment outlook, 49
- cardiac action potential/pacemaker activity, 36–37
- heterogeneity of repolarization and dispersion, 37–38
- integrated risk assessments, 46–49
- predictivity of assays
 - arterially perfused wedge left ventricular preparations, 43–44
 - in silico* predictions, 38–40
 - isolated heart systems, 44
 - measurement of concentration of test article in *in vitro* systems, 44
 - non rodent *in vivo* telemetry, 45–46
 - repolarization assays, 42–43
 - problem status, 34
- QT interval prolongation, 34–35
- regulatory situation, 34–36
- cardiac troponins, 305–306
- cardiovascular system study, 9
- CASETOX system, 158
- CAST. *See* Cardiac Arrhythmia Suppression Trial
- catechols, 108
- cell cycle inhibitors, 206
- CENR (chick embryo neural retina) cell culture model, 160, 165, 167–170
- central nervous system, 8, 187–188
 - See also* autonomic nervous system
- cetirizine, 187–188
- cetuximab (Erbix), 330, 341
- C57B1/6 mouse strains, 270, 279
- Charles River Laboratory, 270
- chemical effects in biological systems (CEBS), 285
- chick embryo neural retina (CENR) cell culture model, 160, 165, 167–170
- children
 - oncology testing, 225–226
 - paroxetine pharmacokinetics measurements, 56
 - pediatric respiratory disease, 330
 - vaccines toxicology study design, 347, 353
- chlamydia vaccine, 345, 357–358
- cholesterol elevation, 76
- cholinergic syndrome, 141
- chronic intermittent hypoxia (CIH), 57
- cirrhosis (of liver), 57
- citalopram, 56
- clarithromycin, 58–59
- clastogenicity screening approaches, 22–26
 - DEL (deletion) recombination assay, 25–26
 - in vitro* comet assay, 25
 - in vitro* micronucleus (IVMN or MN) assay, 22–25
- clinical (drug) databases, 194–195
- clopidogrel (Plavix®), 113
- clozapine, 106, 111
- co-expression networks, 293
- Cockayne's syndrome, 26
- colorectal cancer, 330
- comet assay (*in vitro*), 25
- CoMFA (comparative molecular field analysis) methodology, 39
- Committee for Proprietary Medicinal Products (CPMP) of the European Union, 35
- compound metabolism, as toxicity determinant, 236
- Computer Automated Structure Evaluation (CASE), 158
- congestive heart failure (CHF), 195
- constitutive active/androstane receptor (CAR), 59–60
- corticotropin-releasing factor (CRF) antagonists, 233
- COX-2 inhibitors, 185–186
- CpG motifs, 128
- Cre-expressing mice, 271
- creatine kinase MB (CK-MB), 305–306
- Critical Path Institute, 13, 285, 308, 310
- Crohn's disease, 330
- cyclopamine (shh inhibitor), 254

- cyclopia, 254
 CYP isoforms. *See also* P450 (cytochrome); recombinant P450 isoforms (rCYP)
 contributions using liver microsomes/
 rCYPs (evaluation), 87–88
 enzyme induction potential, 92–93
 inhibitory potential, 88
 liver microsomes, 86
 in vitro evaluation of metabolic drug-
 drug interactions, 79–80
 CYP2D6 gene, 60–61
 cytokines as biomarker, 306
 cytosol, 82
 cytotoxic anticancer agents, 205–206, 314
 cytotoxic anticancer therapeutics, 8
 cytotoxicity
 assessments, 143
 broad-scale assays, 200
 comet formation, 25
 daily dosing as “worst case scenario,”
 220
 dog studies, 215, 318–322
 frank embryotoxicity, 165
 IGE-mediated, 124–125
 in vitro assays, 211
 intact hepatocytes, 89
 liver toxicity vs. general, 194
 P450 induction, 93
 rosiglitazone, troglitazone, 58
 DEL (deletion) recombination assay,
 25–26
 delta-opioid agonist AR-M100390, 237
 Derek Plot (for human DLT dose
 prediction), 317
 DEREK software (for structural alert
 identification), 109–110, 158
 derisking developmental toxicity-mediated
 drug attrition
 embryotoxicity data interpretation,
 164–170
 future perspectives
 in silico SAR mining, 176, 177
 target-specific effects, 175
 in vitro screening, 176–177
 off-target effects, 157–159
 in silico approaches, 158–159
 therapeutic target modulation risk
 assessment, 154–157
 in vitro tests, 159–163
 business need for, 153
 chick embryo neural retina cell culture
 model, 160, 165
 embryonic stem cells, 160–161
 industrial application of, 170–173
 whole embryo culture, 161–162
 zebrafish, 162–163
 dermal system study, 10
 development and reproductive toxicology
 (DART) studies, 11, 351
 developmental neurotoxicity (DNT), 138
 developmental toxicity, 11.
 See also derisking developmental
 toxicity-mediated drug attrition; fish
 embryo models
 chemical mediation of, 164
 EVCAM models, 173
 fish embryo models, 253–256
 human stem cells possible testing use,
 176
 identification/management challenges,
 153
 presence/absence determination, 158
 risk management strategy, 154, 156, 159,
 173–175
 rule-based vs. statistically-based SAR
 approaches, 159
 target proteins and, 155
 testing via murine embryonic stem cells,
 160–161
 in vitro data interpretation, 165–167
 zebrafish-based toxicity model, 162–163,
 165
 dexamethasone, 144
 diabetic nephropathy, 199, 306
 dibenzodiazepine derivatives, 111, 117.
 See also olanzapine
 diclofenac, 106, 292
 diet-induced obesity, 231–232
 diethylene glycol poisoning, 5
 dihydralazine, 104
 dilevalol, 54
 DILI. *See* drug-induced liver injury (DILI)
 diphenhydramine, 116
 diphenylhydantoin, 144
 diphtheria toxin, 339
 DNA
 genomic/viral, 127
 as oncological therapeutic target, 211
 DNA oligonucleotides, 127
 DNA/plasmid vaccine (gene therapy
 product), 346
 DNA vaccines, 352–353
 dog models
 anticancer drug findings, 8
 biochemical integration of, 199
 cardiovascular studies, 9, 45
 cytotoxicity studies, 215
 M cells in, 38
 modeling TK/moribundity, 318–322
 nuclear receptor studies, 97
 oncology testing, 214–215
 toxicogenomics studies, 284
 use of Purkinje fibers from, 43
 in vivo telemetry studies, 36
 dose limiting toxicity (DLT) determination,
 314, 317
 Dow Chemical Company, 161
 doxorubicin, 205–206, 339
 doxycycline, 273

Index

379

- Drosophila* (fly), 146, 189, 190
 drug discovery phase, 1–2
 drug-drug interactions. *See also in vitro*
 assessments, of metabolic drug-drug interactions
 drug-induced liver injury (DILI), 56, 59
 mechanisms of adverse interactions, 76–77
 drug-induced liver injury (DILI), 201
 initiating events/mechanisms of, 64
 multi-hit/multi-step mechanisms of, 62–63, 67
 patients' risk factors for
 toxicodynamic perspective, 56–61
 toxicokinetic perspective, 55–56, 65–67
 prediction strategies, 54–55
 integrated approaches, 64–67
 research direction needs, 67–69
 problems associated with, 54–55
 Drug-Induced Liver Injury Network (DILIN), 310
 drug metabolism (*in vitro* evaluation of metabolic drug-drug interactions)
 phase I oxidation, 78
 phase II oxidation, 78–79
 druggable genome (concept), 154–155
 DrugMatrix (of Entelo), 285, 291
- E-Selectin biomarker, 306
 early after depolarizations (EADs), 38, 42, 49
 ebrotidine, 54
 economics
 and attrition rates, 153
 of bioluminescent Salmonella assay, 22
 of DEL assay, 26
 of FDA-approved medicine, xi
 of fish embryos, 262
 of new chemical entity, 1
 of research (limitations), 272
 ECVAM. *See* European Committee for the Validation of Alternative Methods
 efavirenz (Sustiva®), 236, 238–239
 elderly population, vaccine studies, 353
 Elixir Sulfanilamide (sulphanilamide formulation), 5
 embryonic stem cells (ESTs), 49
 advantages/disadvantages, 167–169
 DEREK software, 159
 developmental toxicity tests, 253
 ECVAM-validated assays, 165
 in vitro tests, 159, 165
 knockout mice, 160–161, 270
 knockout rats, 278
 performance assessment, 169–170
 embryos. *See also* fish embryo models;
 whole embryo culture (WEC)
 CENR cell culture model, 160, 165, 167–170
 frank embryotoxicity, 165
 in vitro/in vivo toxicity data interpretation, 164–170
 encephalopathy, 136
 endocrine system study, 10
 Endothelin biomarker, 306
 ensembl website (for genome sequencing), 246
 enterohepatic nuclear receptors, 59–60
 enzyme linked immunosorbent assay (ELISA) methods, 361
Escherichia coli, 21, 253, 337–338
 estrogen receptors (ER), 59–60
 European Committee for the Validation of Alternative Methods (ECVAM), 161
 assay performance assessment, 169
 EST-/WEC-validated assays, 165
 model design components, 173
 reliance on biostatistical prediction models, 167
 ReProTect initiative, 177
 European Medicines Evaluation Agency (EMA)
 aquatic organism potential toxicity regulations, 260
 preclinical safety data submission, 244
 vaccine testing guidelines, 346, 352
ex vivo biomarkers, 15
 experimental approaches (*in vitro* evaluation of metabolic drug-drug interactions)
 CYP inhibitory potential, 88
 CYP isoform contributions using both liver microsomes and rCYPs (evaluation), 87–88
 empirical interactions, 93
 enzyme induction potential, 92–93
 human hepatocyte studies, 88–89
 IC50, Ki, and [I]/Ki determinations, 89–91
 incubation with individual rCYPs, 86–87
 liver microsome/isoform-selective inhibitors, 86
 studies
 human hepatocyte, 88–89
 human liver microsomes, 87
 liver microsome, 88
 liver microsome/inhibitor study design, 87
 metabolic phenotyping 2-identification of major metabolic pathways, 85
 metabolic phenotyping 1-metabolite identification, 84
 metabolic phenotyping 3-P450 phenotyping, 85
- famotidine, 58–59
 Fanconi's anaemia, 26
 FAO. *See* Food and Agriculture Organization (FAO)

- FAO/WHO Codex Alimentarius, 356
 farnesoid X receptor (FXR), 59–60
 farnesyl, transferase inhibitors, 206
 Federal Food, Drug and Cosmetic Act (of 1938), 5, 6
 felbamate, 54
 fetal death, 154, 165
 Fetal Map (gene expression database), 155, 157
 fexofenadine, 187–188
 First in Human (FIH) studies, 1, 10
 fish embryo models (for drug safety evaluation)
 adult animal tests, 250
 acute and chronic toxicity, 251–252
 developmental toxicity, 253–256
 environmental risk assessment of medicinal products, 260–261
 genotoxicity, 253
 limitations/research perspectives, 261–262
 medaka, 250
 organ toxicity
 cardiotoxicity, 256
 gastrointestinal toxicity, 257–260
 hepatotoxicity, 256–257
 immune response, 260
 neurotoxicity, 257
 renal-failure effects, 260
 reasons for choosing, 246
 zebrafish, 246–250
 fluoxetine, 67
 Food and Agriculture Organization (FAO), 356
 Food and Drug Administration (FDA, U.S.), xi
 aquatic organism potential toxicity regulations, 260
 ArrayTrack championed by, 285
 Biomarker Qualification Review Teams, 308
 biomarker review teams, 310–311
 Critical Path Initiative, 13, 308, 310
 DILI non-approval decisions, 54
 The Future of Drug Safety” report, xi
 mechanism-based drug-drug evaluation approach recommendation, 83
 new drug applications, 76, 230
 Office of Pharmaceutical Science, 11
 oncology drug fast-tracking mechanisms, 204
 pharmacogenomics guidelines, 285
 preclinical safety data submission, 244
 vaccine testing guidelines, 346, 350, 351
 Foundation for the NIH Biomarker Consortium, 310
 Framingham Heart Study, 310
 functional gamma secretase inhibitors (FGSIs), 293
 “The Future of Drug Safety” (U.S. FDA report), xi
 G-protein coupled receptors (GPCRs), 186, 209
 gamma (γ)-secretase inhibitors, 233
 gastrointestinal system study, 9
 gemtuzumab ozogamicin (Mylotarg), 339
 gene expression databases, 155, 157
 See also Fetal Map
 gene expression microarray technology, 303
 Gene Expression Omnibus (GEO), 285
 genetically engineered mice (GEMs) models
 breeding technology
 Cre-Lox system, 271
 genomic vs. cDNA transgenics, 270–271
 breeding timelines, 271
 carcinogenic studies, 276
 heterozygotes/hypomorphs strains, 272
 human risk predictability failures, 274–275
 humanized GEMs
 liver models, 278
 metabolism models, 277
 mouse vs. human targets, 276–277
 knockdowns (siRNA, shRNA, antisense), 272–273
 mouse phenotyping, 271–273
 on-/off-target liability assessment usage, 275
 pitfalls and caveats, 279–280
 strains/background genetics, 269–270
 diabetes mellitus example, 269
 target safety validation usage, 273–275
 genetically engineered rats, 278–279
 genetically modified organism (GMO) medicinal products, 346
 genomic DNA, 127
 genotoxicity testing (screening assays)
 clastogenicity screening approaches, 22–26
 fish models, 253
 goal, 18–20
 mutagenicity screening approaches, 20–22
 stress (SOS) response-based assays, 26–30
 types, 18
 gentamycin, 260
 glomerulopathy, 306
 Good Laboratory Practice (GLP) guidelines, 4, 45, 48, 219
 gradient plate assay (GPA), 20
 green tea (*Camellia sinensis*) toxicity, 59
 GRIND (Grid-INdependent Descriptors)-based 3D-QSAR model, 39
 guinea pig models
 immune complex effects, 10
 in vivo telemetry studies, 36
 M cells, 38
 maximization test, 126

- NKR similarity to humans, 239
- skin sensitization tests, 126
- GVK database, 195
- haemophilus influenza B* (Hib) vaccine, 352, 353, 357
- halothane, 104
- hapten-carrier complexes, 124
- haptens. *See also* immunotoxicology of
 - haptens and nucleic acids
 - drug-induced formation, 57
 - drugs associated with, 104
 - process description, 103
 - T-cell recognition, 104, 124
 - type I to IV immune reaction induction, 124–125
- HazardExpert, 158
- Health Canada/USA, 35
- hematologic system study, 9
- hemolytic anemia, 236
- hepatic system study, 9–10
- hepatic vasculitis, 292
- hepatitis B vaccine, 357
- hepatocyte imaging assay technology (HIAT), 67, 68
- hepatogenous diabetes (HD), 57
- hepatotoxic drugs, 54
- hepatotoxicity (fish models), 256–257
- HER2 positive breast cancer, 330
- Herbalife nutritional supplement
 - contamination, 59
- hERG blockers, 38–43, 49, 184, 186, 191, 193
- hERG (human Ether-a-go-go Related Gene)
 - channel, 37, 211
 - biomarkers, 305
 - cell biology, 41–42
 - early risk assessments/QT interval
 - duration, 44
 - electrophysiology, 40–41
 - in silico* predictions, cardiosafety assays, 38–40
 - in vitro* study with *in vivo* ECG studies, 46–47
 - M cells, 38
 - pharmacophore of chemokine receptor
 - overlap with, 186
 - repolarization assays, 42–43
 - screening timing recommendations, 48
 - TdP, 35
- heterozygote mouse strains, 272
- high blood pressure, 76
- HIV infection, 76, 154
- HIV vaccine, 358
- holoprosencephaly, 254
- human experimental systems (*in vitro*
 - evaluation of metabolic drug-drug interactions)
 - cytosol, 82
 - hepatocytes, 80–81
 - liver microsomes, 85–82
 - liver postmitochondrial supernatant (PMS), 81–85
 - recombinant P450 isoforms (rCYP), 82
- human PBMC (peripheral blood mononuclear cells), 130
- human toxicity predictions, 6. *See also* new chemical entity (NCE) development
 - gaps/additional perspectives, 14–16
 - ILSI-HESI survey, 8
 - meaning/value of in pharmaceutical development, 6
- humanized genetically engineered mice
 - liver models, 278
 - metabolism models, 277
 - mouse vs. human targets, 276–277
- humanized manufactured protein/
 - polypeptides, 4
- hydroquinones, 108
- Hyperpolarization-activated, Cyclic Nucleotide-gated (HCN) family, 37
- hypomorph mouse strains, 272
- Hy's Law, 61
- ibufenac, 54, 111
- ibuprofen, 111–112
- idiosyncratic adverse drug reactions (IADRs). *See also* reactive metabolite formation
 - dose as mitigating factor for, 117
 - evaluating bioactivation potential of
 - new compounds (in drug discovery)
 - covalent binding, 105–106, 114–116
 - reactive metabolites trapping, 104–105, 114–116
 - in silico*/experimental assessment tools, 106–109
 - future research directions, 117–118
 - 1975–1999 black box warnings from, 102
 - reactive metabolites and, 103–104
 - structural alerts
 - drug design, 110–114
 - predictions, 109–110
- IgE-mediated drug hypersensitivity, 124–125
- Immune Epitope Database (IEDB), 356
- immune-mediated IADRs, 103–104
- immunogenicity, 339–340, 349
- immunologic system study, 10
- immunotoxicology of haptens and nucleic acids
 - adaptive immune system mediation of adverse drug reactions, 124–125
 - adverse drug reactions mediated innate immune system
 - nucleic acids stimulating Toll-like receptor 9, 127–129
 - nucleic acids stimulating Toll-like receptors 7 and 8, 129

- immunotoxicology of haptens and nucleic acids (*Cont.*)
- nickel-mediated contact hypersensitivity, 125
- prediction technologies
 - for contact sensitization, 126–127
 - for immune activation by nucleic acids, 130
- in silico* assessments, 3, 4–6
 - ADME predictions of therapeutic concentrations, 167
 - bioactivation potential of new compounds, 106–109
 - Ab Initio* calculations of oxidation potential, 108–109
 - electrochemical oxidations, 106–107
 - virtual predictions of metabolic (bioactivation) sites in molecules, 107–108
 - chemical-based toxicity potential, 211
 - MetaSite* tool, 107–108
 - structure activity (SAR) approaches, 153
- in silico* SAR mining, 176, 177
- in vitro* assessments, 4–6
 - business need for, 153
 - chemistry-related toxicities, 237–238
 - chick embryo neural retina cell culture model, 160, 165
 - chromosomal damage, 18
 - contact sensitization prediction technologies, 126–127
 - cytotoxicity, 211
 - developmental toxicity data interpretation, 165–167
 - DILI, 64
 - embryonic stem cells, 160–161
 - embryonic toxicity data interpretation, 165
 - high throughput electrophysiological screening, 48–49
 - industrial application, 170–173
 - isolated heart systems, 44
 - lead optimization, 153
 - measurement of concentration of test article, 44
 - neurotoxicity
 - mammalian cells, 139–146
 - systems for mechanistic studies, 141–142
 - systems for neurotoxicity screening, 142–146
 - reactive metabolite formation, 104, 105
 - TdP testing strategy, 35
 - toxicogenomics, 287
 - vaccine systems, 360–364
 - whole embryo culture, 161–162
 - zebrafish, 162–163
- in vitro* assessments, of metabolic drug-drug interactions
 - CYP isoforms, 79–80
 - data interpretation
 - P450 induction, 96
 - P450 inhibition, 95–96
 - pathway evaluation, 94–95
 - drug metabolism
 - phase I oxidation, 78
 - phase II oxidation, 78–79
 - experimental approaches
 - CYP inhibitory potential, 88
 - CYP isoform contributions using liver microsomes/rCYPs (evaluation), 87–88
 - empirical interactions, 93
 - enzyme induction potential, 92–93
 - IC50, Ki, and [I]/Ki determinations, 89–91
 - incubation with individual rCYPs, 86–87
 - liver microsome/isoform-selective inhibitors, 86
 - rCYP studies, 88
 - experimental approaches – studies
 - human hepatocyte, 88–89
 - human liver microsomes, 87
 - liver microsome, 88
 - liver microsome/inhibitor study design, 87
 - metabolic phenotyping 2-identification of major metabolic pathways, 85
 - metabolic phenotyping 1-metabolite identification, 84
 - metabolic phenotyping 3-P450 phenotyping, 85
 - human experimental systems
 - cytosol, 82
 - hepatocytes, 80–81
 - liver microsomes, 85–82
 - liver postmitochondrial supernatant (PMS), 81–85
 - recombinant P450 isoforms (rCYP), 82
 - mechanism-based approach for
 - evaluating interaction potential
 - evaluation of inhibitory potential for drug metabolizing enzymes, 83
 - induction potential for drug metabolizing enzymes, 83–84
 - metabolic phenotyping, 83
 - mechanisms of adverse interactions
 - pharmacokinetic, 77
 - pharmacological, 77
 - mechanisms of interaction
 - inductive drug-drug interaction, 83
 - inhibitory drug-drug interaction, 83
 - nuclear receptors (NR), 96–97
 - overview, 76
- in vitro* comet assay, 25
- in vitro* micronucleus (IVMN or MN) assay, 22–25
- advantages of, 23

- ArrayScan approach, 23–25
- flow cytometry approach, 25
- in vivo* assessments
 - chemistry-related toxicities, 237–238
 - chromosomal damage, 18
 - contact sensitization prediction
 - technologies, 126–127
 - early lead optimization, 213–214
 - embryonic toxicity data interpretation, 164–165
 - late lead optimization, 214
 - neurotoxicity/developmental
 - neurotoxicity, 136–139
 - non rodent *in vivo* telemetry, 45–46
 - TdP testing strategy, 35
 - toxicogenomics, 287
 - vaccine toxicological evaluation, 346
- in vivo* testing strategies/models in-use for
 - drug development, 4–6, 7–11
 - DART studies, 11
 - hapten-carrier complexes, 124
 - limitations, 11–14
 - purpose, 7
 - usefulness in patient assessments, 6
- industrial application of *in vitro*
 - assessments, 170–173
- infliximab (Remicade), 330
- influenza vaccine, 346
- infusion reactions (with mABs), 340–341
- injury biomarkers, 304
- injury-response biomarkers, 304
- Innovative Medicines Initiative (European Union), 308, 310
- insulin dependent diabetes mellitus (IDDM) in non-obese diabetic (NOD) mice, 357
- integration studies for DNA vaccines, 352–353
- Intercellular Adhesion Molecule 1 (ICAM-1) biomarker, 306
- International Conference on
 - Harmonization guidelines, 217
 - S7A (*in vivo*), 35
 - S7B (*in vitro*), 35, 45
 - strict adherence limitations, 46
 - vaccine testing, 351
- International Life Sciences Institute-
 - Human and Environmental Sciences Institute (ILSI-HESI), 8, 308
- International Mouse Knockout Consortium, 175
- intracellular domain of Notch (NICD), 293
- intrauterine growth retardation (IUGR), 154, 165
- investigational new drug (IND)-enabling (GLP-compliant) toxicology studies
 - dose setting, 219–220
 - dosing regimens, 220–221
 - reversibility, 221
 - safe starting dose calculations, 221–222
 - investigational new drug (INDs)
 - applications, 223–224, 230
 - ion channels (involved in cardiac action potential/pacemaker activity), 36–37
 - iproniazid, 54
 - Jackson Laboratory, 270
 - juvenile population, vaccine studies, 353
 - KCNH2/hERG transmembrane protein, 352
 - KCNH2 potassium channel, 256
 - kidneys
 - renal system study, 10
 - renal toxicity biomarkers, 306–307
 - Kim-1 nephrotoxicity biomarker, 288, 307
 - kinase inhibitors, 206
 - KineticScan (environmental chamber)
 - from Cellomics, 65
 - knockdowns (siRNA, shRNA, antisense), 272–273
 - knockout-knock-in mice, 276–277
 - knockout-knock-in rats, 278
 - knockout mice, 156
 - ACC2 strain, 231–232
 - BACE1 strain, 273
 - BCI-X_L strain, 231–232
 - breeding timelines, 271
 - C57B1/6 strain, 270
 - described, 210
 - heterozygotes/hypomorphs, value of, 272
 - International Mouse Knockout Consortium, 175
 - limitations in development, 278
 - mouse strain/background genetics, 269–270
 - Phenotype Pfinder program, 156–157
 - phenotyping, 271–272, 274, 275, 279
 - resource requirements, 156
 - SOD2 gene knockout (SOD2+/-) mice, 63
 - for target-related toxicity confirmation, 232–233
 - labetalol, 54
 - Langerhans cells (LCs), 126–127
 - LC₅₀
 - calculation ratio, 167
 - zebrafish, minnow, mice, 251
 - lead molecules, 1, 144
 - lead optimization, integrated approaches
 - ADMET, outline of need, 184–189
 - clinical candidate selection, 188–189
 - hit expansion, 186–187
 - lead nomination, 187–188
 - lead optimization/parallel optimization, 188
 - target selection, 185–186
 - ADMET early profiling components, 189–194
 - in vitro* safety data generation
 - consideration

- lead optimization, integrated approaches (*Cont.*)
 - confidence of data, 191–193
 - relevance of data, 193–194
- in vitro* toxicology, 189–190
- past mistake lessons, 194–195
- in silico* approaches, 195–200
 - decision support tools (data visualization), 196
- in vitro* affinity to effective plasma/tissue concentrations, 198–200
- push toward acceptable therapeutic index, 196–198
- lentiviral delivery systems, 157
- levofloxacin, 58–59
- Li-Fraumeni syndrome, 26
- liver microsomes, 88
 - CYP isoforms, 86, 87–88
- human experimental systems, 85–82
- inhibitor study design, 87
- in vitro* assessment of reactive metabolite formation, 104
- liver postmitochondrial supernatant (PMS), 81–85
- liver safety biomarkers, 307–308
- liver X receptor (LXR), 59–60
- logistic regression modeling, 178, 317–328
- long QT syndrome (LQTS), 37, 38
- lowest-observed-adverse-effect level (LOAEL) benchmark, 214
- LQT testing cascade, 193–194
- Lyme disease, 355
- Lymphoid Tissue Equivalent (LTE) module (in MIMIC™ system), 361
- Lynch syndromes I and II, 26
- M cells (of ventricular myocardium), 38, 43–44
- mABs. *See* monoclonal antibodies (mABs)
- mammalian test systems
 - biochemical integration, 5–6
 - for neurotoxicity assessment, 139–146
- manual patch clamps, 193
- marketing approval cycle, 1
- mathematical modeling
 - mechanistic, of mAB therapeutic index, 331–332
- overview, 330–331
- PK-PD modeling, 330
- predicting efficacy, 332–337
- predicting toxicity
 - antibody-antigen complex, 337–338
 - immunogenicity, 339–340
 - infusion reactions, 340–341
 - uptake of mAB by non-target cells and tissues, 338–339
- matrix metalloproteinase inhibitors, 206
- maximum tolerated dose (MTD)
 - determination, 314
- measles vaccine, 357–358
- mechanism-based approach for evaluating chemistry-related toxicities
 - background information, 235–236
 - compound metabolism as toxicity determinant, 236
 - in-vivo* and/or *in-vitro* studies, 237–238
- mechanism-based approach for evaluating drug-drug interaction potential
 - evaluation of inhibitory potential for drug metabolizing enzymes, 83
- induction potential for drug metabolizing enzymes, 83–84
- metabolic phenotyping, 83
- mechanism-based toxicity studies (for drug development)
 - background information, 230–231
 - evaluation approaches, 231–235
 - inactive enantiomers, 234–235
 - knockout animals, 232–233
 - SiRNA technology, 234
 - tissue distribution, 231–232
- impact on integrated risk assessment for a development molecule, 238–240
- mechanistic mathematical modeling of mAB therapeutic index, 331–332
- medaka (*Oryzias latipes*), 250, 254
- medulloblastomas, 254
- meloxicam, 64, 116
- metabolic drug-drug interactions. *See in vitro* assessments, of metabolic drug-drug interactions
- MetaCore/MetaDrug (GeneGo), 293
- MetaSite (*in silico* tool), 107–108
- methylmercury, 143, 144
- metoprolol, 111
- micronucleus (MN) assay. *See in vitro* micronucleus (IVMN or MN) assay
- miRNA (microRNAs), 303
- Modular Immune *in vitro* Construct technology system (MIMIC™), 360–361
- monkey models
 - CAR activity, 97
 - cardiovascular testing, 49
 - nuclear receptor studies, 97
 - in vivo* telemetry studies, 36
- monoclonal antibodies (mABs)
 - brands/types of, 330
 - mechanistic mathematical modeling predicting efficiency, 332–337
 - predicting toxicity, 337–341
 - therapeutic index, 331–332
 - pharmacokinetics of, 331
 - uptake by non-target cells/tissues, 338–339
- mouse models. *See* genetically engineered mice (GEMs) models; knockout mice
- MTD (maximum tolerated dose)
 - determination, 314

Index

385

- multi-hit hypothesis for drug-induced liver injury (DILI), 62–63, 67
- MultiCASE® in silico system, 4, 158
- multiple kinase screens, 212
- mutagenicity screening approaches, 20–22
 - Ames II assay, 21
 - biofluorescence test, 21
 - bioluminescence testing, 21–22
 - gradient plate assay (GPA), 20
 - Miniscreen assay platform, 20
 - Multiscreen assay platform, 20–21
 - Salmonella* spiral modification assay, 20
- National Academy of Sciences, 293
- National Cancer Institute Toxicity Criteria, 206
- National Human Genome Research Institute, 293
- National Institute of Environmental Health Sciences (NIEHS), 285
- National Institutes of Health, 270, 310
- NDAs. *See* new drug applications (NDAs)
- nefazodone, 58–59, 67, 108, 116
- nervous system. *See also* autonomic nervous system, central nervous system
 - anatomy/functions, 135
 - blood brain barrier protection, 136
 - neurotoxicity, 135
 - developmental exposure, 138
 - secondary effects, 136
 - in vitro* testing models, 139–140, 141–142
- NET (neuropathy target esterase), 141
- neurokinin receptor (NK) antagonists, 239
- neuroleptic drugs, 108.
 - See also* remoxipride
- neurotoxicity
 - causes (reasons for occurrence), 136
 - defined, 135–136
 - developmental neurotoxicity, 138
 - known compounds, 135–136
- neurotoxicity assessment
 - alternate model development, 148
 - guidelines
 - Cosmetics Directive (76/768/EEC), 138
 - OECD, 136
 - REACH, 138
 - USEPA, 136
 - non-mammalian testing models, 146–147
 - in vitro* testing
 - mammalian cells, 139–146
 - systems for mechanistic studies, 141–142
 - systems for neurotoxicity screening, 142–146
 - in vivo* testing, 136–139
 - guidelines, 148
 - new chemical entity (NCE) development.
 - See also in vivo* testing strategies/
 - models in-use for drug development
 - challenges, 184
 - costs, 1
 - and drug discovery phase, 1–2
 - hepatotoxicity study, 9–10
 - in silico/in vitro* evaluations, 4–5
 - patient risk/benefit assessments, 6
 - pharmacological target safety evaluations, 230
 - risk assessments for aromatic amine, amide, sulfonamide group, 235
 - safety profile inclusions, 7
 - new drug applications (NDAs), 76, 205, 230
 - NFκB (transcription factor), 60
 - nickel-mediated contact hypersensitivity, 125
 - nimesulide, 58–59
 - nitric oxide biomarker, 306
 - nitrogen mustards, 211
 - no-observed-adverse-effect level (NOAEL)
 - benchmark, 214
 - no-observed-effect level (NOEL)
 - benchmark, 214
 - nomifensine, 54
 - non-alcoholic fatty liver disease (NAFLD), 57, 58
 - non-Hodgkin's lymphoma, 330
 - Nonclinical Evaluation for Anticancer Pharmaceuticals* (ICH S9 guidance document), 219
 - The Nonclinical Evaluation of the Potential for Delayed Ventricular Polarization (QT Interval Prolongation)* (ICH S7B), 223
 - nonmammalian models for neurotoxicity assessment, 139–146
 - nonnucleoside reverse transcriptase inhibitors (NNRTIs), 56, 236, 238–239.
 - See also* efavirenz (Sustiva®)
 - nonsteroidal anti-inflammatory drugs (NSAIDs), 111–112. *See also* tolmetin, zomepirac
 - Notch intracellular domain (NICD), 293
 - Nrf2 (nuclear factor-erythroid 2-related factor 2), 60
 - NSAIDs. *See* nonsteroidal anti-inflammatory drugs (NSAIDs)
 - nuclear receptors (NR), 59–60, 96–97, 195.
 - See also* constitutive active/androstane receptor; estrogen receptors; farnesoid X receptor; liver X receptor; pregnane X receptor
 - nucleic acids
 - stimulation of TLR 9, 127–129
 - stimulation of TLR 7 and 8, 129
 - nucleoside analogs, 211

- obesity (diet-induced), 231–232
- Office of Pharmaceutical Science (FDA), 11
- olanzapine (Zyprexa®), 117
- oligodeoxynucleotides (ODNs), 127–128, 129, 130
- omeprazole, 114
- omics data, integrative pathway/network analysis
 - knowledge-driven integrated omics, 295–296
 - Random Forests, 296–297
- oncology drugs/therapy
 - candidate database building, 215–217
 - candidate progression criteria, 217
 - candidate selection challenges, 207–217
 - adverse effect classifications, 207–209
 - lead optimization-early
 - in vitro* considerations, 211–213
 - in vivo* considerations, 213–214
 - lead optimization-late, 214
 - target validation, 209–210
 - cytotoxic agents, 205–206
 - FDA fast-track mechanisms, 204
 - IND-enabling (GLP-compliant)
 - toxicology studies
 - dose setting, 219–220
 - dosing regimens, 220–221
 - reversibility, 221
 - safe starting dose calculations, 221–222
 - investigational new drug (IND)
 - application, 223–224
 - late-stage cancer patient, 205–206
 - longer-term toxicity studies, 224–225
 - pediatric testing/combination therapy
 - considerations, 225–226
 - progression from late-stage to front-line therapy, 225
 - safety pharmacology, 222–223
 - testing benchmark dose definitions, 214–215
 - toxicology/pathology challenges, 206–207
- organ function biomarkers, 304
- organ system studies
 - cardiovascular, 9
 - central nervous system, 8
 - dermal, 10
 - endocrine, 10
 - gastrointestinal, 9
 - hematologic, 9
 - hepatic, 9–10
 - immunologic, 10
 - pulmonary, 10
 - renal, 10
- organ toxicity (fish embryo models)
 - cardiotoxicity, 256
 - gastrointestinal toxicity, 257–260
 - hepatotoxicity, 256–257
 - immune response, 260
 - neurotoxicity, 257
 - renal-failure effects, 260
- Organization for Economic Co-operation and Development (OECD), 136, 253
- organophosphorus (OP) compounds, 141
- Osanetant (NKR antagonist), 239
- P450 (cytochrome). *See also* CYP isoforms
 - induction outcomes, 96
 - inhibition study outcomes, 95–96
 - inhibitory potential, 88
 - mediated bioactivation of
 - acetaminophen, 103
 - potassium channel opener, maxipost (BMS-204352), 105
- P-Selectin biomarker, 306
- palivizumab (Synagis), 330
- PAMAM (polyamidoamine) dendrimers, 251–252
- para*-hydroxyacetanilides, 108
- Paracelsus, 7
- paraquat, 145
- paroxetine, 64, 116
- paroxetine pharmacokinetics, 56
- Pathway Analysis suite (Ingenuity), 293
- Pathway Studio (Ariadne), 293
- PBMC (peripheral blood mononuclear cells), human, 130
- PDE3 inhibition, 195
- penicillin, 124
- perhexiline, 54, 60–61
- peripheral blood mononuclear cells (PBMCs), 127
- Peripheral Tissue Equivalent (PTE) module (in MIMIC™ system), 360–361
- Pertussis Toxin Pathway, 297
- pertussis vaccine, 345, 352, 353
- Pfizer Phenotype Pfinder program, 156–157
- pharmaceutical research and development (R&D) model, xi
- pharmacokinetic-pharmacodynamic (PK-PD) modeling, 315, 330
- Pharmacological Basis of Therapeutics* (Goodman and Gilman), 205
- Pharmapendium database, 195
- Phenotype Pfinder program (Pfizer), 156–157
- phenotyping of knockout mice, 271–272, 274, 275, 279
- Phylonix-Bristol Myers-Squibb test
 - collaboration, 170
- pig (minipigs) models
 - cardiovascular testing, 49
 - intradermal/patch dosing assessments, 349
- pioglitazone, 64, 107
- PK-PD modeling. *See* pharmacokinetic-pharmacodynamic (PK-PD) modeling

- polybrominated diphenyl ethers (PBDEs), 136
 polychlorinated biphenyls (PCBs), 136, 143–144
 polymorphic ventricular tachycardia, 34
 polyneuropathy, 136
 postmitochondrial supernatant (PMS), 81–85
 PPARs (transcription factor), 60, 234
 See also troglitazone
 prazosin (Minipress®), 117
 pre-clinical IND-supporting studies, 3
 predictive biomarkers, 304–305
 Predictive Safety Testing Consortium (PSTC), 13, 285, 307
 pregnane X receptor (PXR), 59–60
 procollagen type III amino terminal peptide (PIIINP), 306
 Proctor and Gamble (chick embryo neural retina cell culture model), 160
 prohaptens, 124–125
 propranolol, 116
 protease inhibitors (PIs), 56
 proteasome inhibitors, 206
 protein (manufactured)/polypeptides, 4
 protein-protein interaction networks, 293
 proton-pump inhibitors (benzimidazole class), 114
 pulmonary system study, 10
 purinome inhibitors, 206
 purpose-designed manufactured protein/polypeptides, 4

 QT interval prolongation, 34–35
 biomarkers, 305
 early drug risk assessments, 44
 non rodent *in vivo* telemetry studies, 45–46
 TdP marker, 48
 verapamil, 42–43
 quantitative-structure-activity relationships (QSAR), 2, 4, 39, 148, 186
 quetiapine (Seroquel®), 111

 rabbit models
 IM injection testing, 349
 nuclear receptor studies, 97
 as reproductive model, 350
 use of Purkinje fibers from, 43
 radioligand binding, 186
 raloxifene, 115–116
 random forest algorithm, 67, 295–297
 ranitidine, 58–59
 rat models
 CAR activity, 97
 genetically engineered rats, 278–279
 knockout-knock-in rats, 278
 modeling TK/severity of lesions, 322–323
 nuclear receptor studies, 97
 oncology testing, 214–215
 teratogenicity measures, 237–238
 toxicogenomics studies, 284
 reactive metabolite formation (evaluation by experimental methodology)
 covalent binding, 105–106, 114–116
 in vitro assessment of, 104, 105
 structural alert predictions, 109–110
 trapping of reactive metabolites, 104–105, 114–116
 reactive metabolites and idiosyncratic drug toxicity, 103–104
 reactogenicity (local tolerance) safety endpoint for vaccines, 349
 receptor and enzyme screens, 211–212
 receptor inverse agonist SB-236057, 237–238
 receptor tyrosine kinase (RTK) inhibitor, 212
 recombinant P450 isoforms (rCYP), 82, 86–88
 recombinant plasmid DNA anti-rabies vaccine, 346
 remoxipride, 108
 renal system study, 10
 renal toxicity biomarkers, 306–307
 repolarization assays, 42–43
 reproductive/developmental studies of vaccines, 349–352
 ReProTect initiative (ECVAM), 177
 respiratory syncytial virus (RSV) vaccine, 345, 357–358
 rheumatoid arthritis, 330
 RIG-I-like receptors (RLRs), 129
 risk assessment, of therapeutic target modulation. *See* therapeutic target modulation risk assessment
 risk factors for drug-induced liver injury (DILI)
 toxicodynamic perspective, 56–61
 toxicokinetic perspective, 55–56
 rituximab (Rituxan), 330, 341
 RNA-activated protein kinase (PKR), 129
 RNA-induced silencing complex (RISC), 129
 rosiglitazone, 58, 107

S9 Guidance for Nonclinical Evaluation for Anticancer Pharmaceuticals (International Conference on Harmonization), 217, 224
 safety biomarkers. *See* biomarkers for drug safety
 safety pharmacology-related endpoints, 222–223
Safety Pharmacology Studies for Human Pharmaceuticals (ICH S7A), 223
 safety-risk management decision-making, 14

- Salmonella* assay platforms, 19
 Ames II assay, 21
 bioluminescence testing, 21–22
 gradient plate assay (GPA), 20
 spiral modification assay, 20
 SANT-2 compound, 255
 SB-236057 (receptor inverse agonist),
 237–238
 SCH 06272 (NKR antagonist), 239
 short QT syndrome (SQTS), 38
 shRNA (small hairpin RNA), 157, 272–273,
 278
 signal transduction inhibitors, 206
 simian reassortant rotavirus vaccine, 345
 simvastatin, 116
 siRNA (small interfering RNA), 130, 234,
 272–273
 smallpox vaccine, 346
 SOD2 gene knockout (SOD2+/-) mice, 63
 sonic hedgehog signaling (shh) pathway,
 254
 species selection, in vaccine toxicology
 study design, 347–348
 speed congenics (with knockout mice), 270
 Sprague-Dawley rat, 279
 Squibb-Briston Myers-Phylonix test
 collaboration, 170
 Stat-3 (transcription factor), 60
 steatohepatitis, 62
 stress (SOS) response-based screening
 assays, 26–30
 structure-activity relationship (SAR), 186
 IC₅₀ or EC₅₀ support, 191
 in silico approaches, 153, 158–159,
 174–177, 195–200
 in vivo/in vitro assays, 237, 372
 sulphanilamide formulation (Elixir
 Sulfanilamide), 5
 superoxide dismutase 2 (SOD2) gene
 knockout (SOD2+/-) mice, 63
- T-cells
 drug allergies and, 125
 hapten recognition by, 104, 124
 nickel-mediated receptor stimulation,
 125
 response to Ni-MHC-peptide complexes,
 125
 in vitro proliferation, 127
 tadalafil (Cialis®), 117
 Talnetant (NK3 antagonist), 239
 target-related toxicity (evaluation methods)
 inactive enantiomers, 234–235
 knockout animals, 232–233
 siRNA (small interfering RNA), 234
 tissue distribution, 231–232
 target safety validation and use of GEMs,
 273–275
 tasosartan, 54
 telithromycin, 54, 58–59, 68
 temafloxacin, 54
 teratogenicity, 103
 attrition rates attributed, 230–231
 causes (determinants), 154, 167
 developmental toxicity, 153
 drug candidate attrition due, 177
 in rats given SB-236057 (receptor inverse
 agonist), 237–238
 in vitro screening, 231, 238
 in vivo screening, 177, 231
 tetracycline, 273
 therapeutic target modulation risk
 assessment
 developmental toxicity management
 strategy, 154
 genetically modified animal models,
 155–157
 target determination, 154–155
 target-mediated vs. chemotype-mediated
 teratogenesis, 154
 ticrynafen, 54
 tienilic acid, 54, 104, 116
 tissue distribution, to evaluate target-
 related toxicity, 231–232
 TK (commonly used) parameters, 314
 TK/PD (toxicokinetic/pharmacodynamic)
 modeling applications
 bridging preclinical data to humans,
 325–326
 case studies
 lesions in rat tissues, 322–323
 moribundity from dogs, 318–322
 concepts and considerations, 315–317
 description and purpose, 315
 dose limiting toxicity determination, 314
 limitations, 324–325
 logistic regression models, 317–318
 maximum tolerated dose determination,
 314
 tolcapone, 54, 106
 Toll-like receptors (TLRs)
 9 (nine), 127–130
 7 (seven) and 8 (eight), 129–130
 tolmetin, 112
 Torsade de pointes (TdP), 34, 47
 hERG channel, 35
 markers, 48, 305
 ToxExpress (of GeneLogic), 285
 Toxicity Predictions by Komputer Assisted
 Technology (TOPKAT), 158
 toxicodynamic risk factors for DILI, 56–61
 disease states, 57–58
 drug-drug interactions, 59
 genetics of receptors, transcription
 factors, enzymes, transporters,
 59–61
 host immune system and responses,
 58–59
 lifestyle/fat mass influences, 58
 nutritional status, 58

- nutritional supplement/herbal extract interactions, 59
- toxicogenomics
 - applications/challenges, 286–290
 - background information, 284–285
 - biological pathways and networks, 292–294
 - microarray assessment, 289
 - omics data, integrative pathway/network analysis
 - knowledge-driven integrated omics, 295–296
 - Random Forests, 296–297
 - study design, 290–292
- toxicokinetic risk factors for DILI, 55–56, 65–67
 - age, 55
 - gender, 55–56
- ToxShield (Gene Logic), 291
- trans*-retinoic acid, 144
- transcription factors
 - genetics, 59–61
 - ligand-activated, 96
 - toxicant response modulation, 60
- trastuzumab (Herceptin), 330, 338, 341
- TRIaD technology (Triangulation, Reverse use-dependence, Instability and Dispersion), 44
- trimethoprim, 106
- trimethyltin, 145
- troglitazone, 54, 58, 63, 106
- Troponin proteins, 305
- trovafloxacin, 54, 58–59, 68
- type 2 diabetes mellitus, 57, 76, 231–232
- United States Environmental Protection Agency (USEPA), 136
- urushiol (prohaptan from poison ivy), 124
- vaccine toxicology
 - allergy/hypersensitivity reactions, 357–358
 - enhanced disease (immunopathology), 357–358
 - immunopharmacotoxicology, 353–357
 - autoimmunity and animal models, 357
 - autoimmunity and bioinformatics, 355–356
 - autoimmunity risk and vaccination, 353–354
 - predicting autoimmunity, 354–355
 - overview, 344–345
 - predictive *in vitro* systems, 360–364
 - predictive strategies, 345–353
 - biodistribution studies, 352
 - design of toxicology studies, 347
 - developmental and reproductive toxicity (DART) studies, 349–352
 - elderly/juvenile populations, 353
 - general toxicology studies, 346
 - immunogenicity evaluation, 349
 - integration studies, 352–353
 - in vivo* toxicological evaluation, 346
 - reactogenicity (local tolerance), 349
 - safety pharmacology studies, 352
 - species selection, 347–348
 - safety considerations
 - adjuvants, 359–360
 - biomarkers, genomics, proteomics, 360
 - DNA vaccines, 358–359
 - toxins, 359
 - types of vaccines, 344–345
 - valproic acid, 144
 - vasoactive hormone biomarkers, 306
 - verapamil
 - balancing of hERG channel inhibition, 190
 - QT interval prolongation, 42–43
 - viral DNA, 127
 - von Willebrand factor biomarker, 306
- Wajima method (for human DLT dose prediction), 317
- Werner's syndrome, 26
- whole embryo culture (WEC), 161–162, 167
 - advantages/disadvantages, 167–169
 - ECVAM-validated assays, 165
 - performance assessment, 169–170
- Wiscott-Aldrich syndrome, 26
- World Cancer Report (2008), 204
- World Health Organization (WHO).
 - See also* FAO/WHO Codex Alimentarius
 - foodstuff modification guidelines, 356
 - vaccine testing guidelines, 346
- xenobiotic bioactivation, 103
- xeroderma pigmentosum, 26
- ximelagatran, 54
- zebrafish (*Danio rerio*), 146–147, 162–163, 190, 246–250. *See also* fish embryo models (for drug safety evaluation)
 - cardiotoxicity studies, 256
 - gastrointestinal toxicity studies, 257
 - hepatotoxicity studies, 256–257
 - immune response studies, 260
 - neurotoxicity studies, 257
- zileutin, 54
- zolpidem (Ambien®), 114
- zomepirac, 112